

Methodology

Open Access

## Analysis of adenoviral attachment to human platelets

Nilly Shimony<sup>1</sup>, Gregory Elkin<sup>1</sup>, Dror Kolodkin-Gal<sup>2</sup>, Lina Krasny<sup>1</sup>,  
Simcha Urieli-Shoval<sup>3</sup> and Yosef S Haviv\*<sup>1</sup>

Address: <sup>1</sup>Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 91120, <sup>2</sup>Department of Virology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 91120 and <sup>3</sup>Department of Hematology Mount Scopus, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 91120

Email: Nilly Shimony - nillys@pob.huji.ac.il; Gregory Elkin - elkin@hadassah.org.il; Dror Kolodkin-Gal - drorgal@pob.huji.ac.il; Lina Krasny - lalushka82@yahoo.com; Simcha Urieli-Shoval - simcha@hadassah.org.il; Yosef S Haviv\* - yhaviv@hadassah.org.il

\* Corresponding author

Published: 17 February 2009

Received: 12 January 2009

*Virology Journal* 2009, **6**:25 doi:10.1186/1743-422X-6-25

Accepted: 17 February 2009

This article is available from: <http://www.virologyj.com/content/6/1/25>

© 2009 Shimony et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Systemic adenoviral (Ad) vector administration is associated with thrombocytopenia. Recently, Ad interaction with mouse platelets emerged as a key player determining liver uptake and platelet clearance. However, whether Ad can activate platelets is controversial. Thus, *in vitro* analysis of Ad attachment to platelets is of interest.

**Methods:** We developed a direct flow cytometry assay to specifically detect Ad particles adherent to human platelets. The method was pre-validated in nucleated cells. Blocking assays were employed to specifically inhibit Ad attachment to platelets. Platelet activation was analyzed using annexin v flow cytometry.

**Results:** We found *in vitro* that Ad binding to human platelets is synergistically enhanced by the combination of platelet activation by thrombin and MnCl<sub>2</sub> supplementation. Of note, Ad binding could activate human platelets. Platelets bound Ad displaying an RGD ligand in the fiber knob more efficiently than unmodified Ad. In contrast to a previous report, CAR expression was not detected on human platelets. Integrins appear to mediate Ad binding to platelets, at least partially. Finally,  $\alpha$ IIb $\beta$ 3-deficient platelets from a patient with Glanzmann thrombasthenia could bind Ad 5-fold more efficiently than normal platelets.

**Conclusion:** The flow cytometry methodology developed herein allows the quantitative measurement of Ad attachment to platelets and may provide a useful *in vitro* approach to investigate Ad interaction with platelets.

### Background

Thrombocytopenia is a major adverse effect of high dose systemic administration of adenoviral (Ad) gene therapy vectors. While a previous report did not find platelet activation by Ad [1], recent studies have shown that Ad may activate platelets [2] and binds *in vivo* to murine thrombo-

cytes resulting in hepatic sequestration [3]. Ad-induced thrombocytopenia has been shown to be dose-dependent, saturable and reversible [4], compatible with a ligand-receptor mechanism. Recently, binding of Ad to platelet was indirectly suggested following interference of platelet adhesion to fibronectin after incubation with Ad

[2]. In this study we developed a direct flow cytometry assay to quantitatively analyze Ad attachment to human platelets *in vitro* and to characterize their interaction.

Many microorganisms in addition to Ad have evolved to facilitate cell entry via RGD recognition of cell surface integrins. For example, integrins mediate RGD-dependent attachment of picornaviruses [5,6] and bacteria [7,8]. In contrast, Group C Ad primarily attaches to the cell surface via the fiber protein knob binding to CAR [9] (coxsackie and Ad receptor). Next, Ad internalizes primarily utilizing  $\alpha V\beta 3$  integrin [10], and to a lesser extent  $\alpha V\beta 5$  integrin [11], via interaction of the RGD-containing Ad penton base protein. In addition to  $\alpha V\beta 3$  and  $\alpha V\beta 5$ , other integrin receptors for Ad may include  $\alpha V\beta 1$ , and  $\alpha 5\beta 1$  [12]. Because Ad uses both CAR and  $\alpha V$  integrins, we used our flow cytometry assay to evaluate CAR expression in platelets and integrin-mediated Ad binding to platelets.

## Results

### Human platelets bind Ad particles

To characterize attachment of Ad group C (serotype 5) to human platelets we employed a direct flow cytometry assay on human platelets using a FITC-labeled anti-Ad hexon antibody (see materials and methods section). First, we calibrated the system measuring Ad attachment to nucleated cells (Fig. 1), derived from isogenic human melanoma cell lines stably expressing either the Ad integrin receptor  $\alpha V\beta 3$  or the platelet integrin  $\alpha IIb\beta 3$  [13]. The specific integrin expression profile in these cells was confirmed with indirect flow cytometry (not shown). Ad binding to the cell surface of these cell lines (measured in 4°C) was similar, comprising two main populations, i.e. a small cell population binding Ad with high affinity and a larger population binding Ad with medium affinity (Fig. 1a). Of note, expression of the primary Ad attachment receptor, CAR, was practically absent in Mo cell lines (see below), thereby suggesting that surface integrins suffice to mediate Ad attachment in these cells. To discern in these nucleated cells cell surface Ad binding from infection, we also allowed cell entry (in 37°C) following infection with Ad encoding GFP (AdGFP) and measured transgene expression by direct flow cytometry (Fig. 1b). These distinct flow cytometry assays could clearly differ between  $\alpha V$ -enhanced Ad cell entry (Fig. 1b) and  $\alpha V$ -independent Ad surface attachment (Fig. 1a).

Next, we employed direct flow cytometry to detect and characterize attachment of Ad to platelets. To this end, the unique flow cytometry appearance of platelets could allow their specific gating, further confirmed by platelet stain with anti-CD41 ( $\alpha IIb\beta 3$ ), an integrin expressed uniquely in platelets (Fig. 2a). Human platelets were incubated with Ad, rinsed and incubated with FITC-labeled anti-Ad hexon antibody prior to flow cytometry. This

strategy allowed quantitative identification of Ad particles adherent to the platelet surface (Fig. 2c). There was no cross-reactivity of FITC-labeled anti-Ad hexon antibody with human platelets (Fig. 2b). Platelet activation by thrombin did not affect Ad attachment to platelets (Fig. 2d), and  $Mn^{+2}$  supplementation marginally enhanced Ad attachment (Fig. 2e). However, combining  $Mn^{+2}$  supplementation with thrombin activation substantially enhanced Ad attachment to platelets (Fig. 2f).



A previous report suggested that *in vitro* incubation of Ad with human platelets failed to aggregate platelets [1]. In contrast, systemic Ad injection could induce platelet activation *in vivo* [2,3] and enhanced platelet clearance [4]. To clarify this issue we measured exteriorization of the platelet membrane phosphatidylserine using annexin stain (indicating apoptosis in nucleated cells but serving as a marker of activation in platelets [14]) and observed that Ad could efficiently activate human platelets *in vitro* (Fig. 2g,h). To optimize the conditions of Ad-platelet binding we tested several MOIs and FITC anti-hexon antibody concentrations (Fig. 3) and found that an MOI of 10 is optimal for Ad binding and that dilution of the FITC anti-hexon antibody resulted in a reduced Ad signal. Thus, Ad attachment to human platelets can be characterized *in vitro* using direct flow cytometry.

### Ad virions adhere to the platelet surface

To discern between platelet cell entry vs. Ad attachment to the platelet membrane, we employed two methods. First, Ad was incubated with platelets either at 37°C or 4°C, the latter precluding cell entry [10]. In addition, Ad were incubated either with live or fixed platelets, the latter also precluding cell entry. Our data indicate that Ad-platelet interaction solely involves adherence to the cell surface (Fig. 4a). Confocal immunofluorescent microscopy qualitatively confirmed attachment of Ad virions to the platelet surface (Fig. 4b).


### Ad binds to platelet surface integrins

Next, we employed flow cytometry to evaluate the mechanism of Ad binding to the platelet surface. Ad displaying an RGD ligand in the HI fiber knob loop adhered more efficiently to platelets than unmodified Ad (Fig. 5a) and a variety of RGD-based ligands could block Ad attachment to platelets (Fig. 5b). However, GRGDS (RGD) was less efficient vs. eptifibatide (a synthetic analog based on the barbourin motif, containing a homoArginine-Glycine-Aspartate sequence), or vs. the FBG carboxy terminus 400–411 dodecapeptide ( $C\gamma$ ). These two peptides could efficiently (6-fold) block platelet Ad binding. A monoclonal anti- $\alpha V\beta 3$  antibody could also specifically, but only partially, block Ad attachment to platelets (Fig. 5c). Because  $\alpha V\beta 3$  expression on platelets is minute [15], these data may indicate a high affinity of Ad to platelet  $\alpha V\beta 3$ . Of



**Figure 1**

**Flow cytometry to detect Ad attachment to nucleated human cells.** (a) One million cells of the isogenic human melanoma cell lines Mo and the stably-transfected Mo-αVβ3 and Mo-αIIbβ3 cell lines (respectively expressing αVβ3 integrin and the platelet αIIbβ3 integrin) were incubated with Ad (MOI = 10, 4°C, 1-hr), followed by rinse and staining with a FITC-labeled anti-Ad hexon antibody. The negative control comprised omitting Ad. Histograms show the distribution and fluorescence intensity of Ad bound to the cell surface (b) Ad infection in the above cell lines was studied using a replication deficient Ad vector expressing GFP (AdGFP). Cells were incubated with AdGFP at an MOI of 10 for 4 hours at 37°C, medium replaced and cells further cultured for 18-hrs. Intracellular GFP expression was measured using flow cytometry. \*, *p* < 0.05 for enhanced Ad infection of Mo-αVβ3 vs. Mo cells and Mo vs. Mo-αIIbβ3 cell. Representative images of at least 2 different experiments (*n* = 3 for each).



**Figure 2** (see legend on next page)

**Figure 2** (see previous page)

**Characterization of Ad binding to human platelets.** Platelets were isolated from platelet-rich plasma as described in Materials and Methods. Platelets were incubated with Ad (MOI = 10, 1 hr, RT), followed by a thorough rinse and incubation with a FITC-labeled anti-Ad hexon antibody (1:1 dilution, 4°C, 1-hr). Direct flow cytometry was used to measure Ad binding as FITC-positive platelet events (a) Platelets were gated by their characteristic forward light scatter and labeling with an anti- $\alpha$ IIb $\beta$ 3 ( $\alpha$ -CD41) antibody. (b) To exclude non-specific recognition of unbound platelets by the anti-Ad hexon antibody, the negative control comprised omitting Ad and incubating platelet directly with the antibody. (c) The degree of Ad attachment to platelets was measured by staining with the FITC-anti Ad hexon antibody. (d) To evaluate the effect of platelet activation on Ad binding, platelets were first activated by thrombin (0.5 U/ml, 20 min, RT), rinsed and incubated sequentially as above with Ad and stained by the anti-Ad hexon antibody. (e) To measure the effect of divalent ion supplementation on Ad attachment,  $MnCl_2$  (5 mM) was added prior to Ad incubation. (f) Enhancement of Ad attachment to platelets by sequential thrombin activation and  $MnCl_2$  supplementation. (g, h) Ad incubation activates platelets. Platelet activation was measured using annexin staining, reflecting exteriorization of phosphatidylserine, either w/o Ad (g) or w/Ad (MOI = 10, RT, 1-hr) (h). All figure data representative of at least 2 different experiments ( $n = 3$  for each).

note, while previous studies showed a role for heparan sulfate proteoglycans in Ad binding to nucleated cells [12], heparan sulfate does not appear to play a role in Ad binding to platelets as several doses of heparin did not block Ad attachment to platelets (not shown).

Expression of CAR, the primary Ad attachment receptor on nucleated cells, has been recently reported in platelets [2]. However, in our studies CAR expression was not detected on human platelets (Fig. 6), confirmed by negative (Mo cells) and positive (HEK 293 cells) nucleated cell controls for CAR expression. Taken together, our data indicate a role for integrins in mediating Ad binding to human platelets *in vitro*.

#### **Enhanced Ad attachment in Glanzmann Thrombasthenia platelets**

We next sought to evaluate Ad binding to platelets deficient of the integrin  $\alpha$ IIb $\beta$ 3 (also called gpIIb/IIIa) from a patient with Glanzmann thrombasthenia (GT). GT mutations in the  $\alpha$ IIb $\beta$ 3 gene result in a bleeding tendency because  $\alpha$ IIb $\beta$ 3 expression is either abolished or the fibrinogen (FBG) binding domain is disrupted [1]. Consequently, platelet adhesion and aggregation are impaired, resulting in life-long bleeding diathesis. The mutation in the kindred to which this patient belongs comprises complete abolition of  $\alpha$ II $\beta$  expression while  $\alpha$ 3 expression is maintained to a small extent. Thus, a small degree of  $\alpha$ V $\beta$ 3 platelet expression may be preserved in GT [15]. We first confirmed that platelets from the patient with GT had practically no  $\alpha$ IIb $\beta$ 3 expression (Fig. 7a), and were functionally impaired as evident by both reduced platelet attachment to FBG (Fig. 7b) and decreased activation by thrombin (not shown). Surprisingly, GT platelets bound Ad 5-fold more efficiently than normal platelets (Fig. 7c).


#### **Discussion**

Platelets bind physiological ligands in an RGD-dependent manner, e.g. FBG, von Willerband factor (VWF), fibronectin and vitronectin. Non-physiological platelet integrin ligands include disintegrins (cyclic RGD-based polypeptides in snake venoms) and a number of microorganisms.


One of the most extensively characterized pathogens with respect to nucleated cellular integrin interaction is Ad. Cell entry by Ad viruses initially involves attachment of the Ad fiber knob to the primary Ad receptor, CAR [6], followed simultaneously or subsequently by binding of any of the five RGD protrusions on the Ad penton base protein to cellular  $\alpha$ V integrins heterodimerized to specific  $\beta$  chains [10,11]. A critical requirement for Ad infection is the interaction of membrane  $\alpha$ V integrin with the RGD-displaying Ad penton base. This interaction has been previously demonstrated via inhibition of Ad cell entry by RGD peptides and antibodies to  $\alpha$ V integrins [10,16]. Integrin receptors are heterodimers comprised of  $\alpha$  and  $\beta$  subunits whose specific sequence and activation-dependent conformation determine their ligand affinity. The ligand motif for a number of integrins is based on an arginine-glycine-aspartate (RGD) sequence and variations on the RGD theme determine specific ligand-integrin recognition. For example, fibrinogen (FBG) binding to  $\alpha$ IIb $\beta$ 3 depends on prior inside-out signaling, resulting in platelet priming and conformational  $\alpha$ IIb $\beta$ 3 transition into a high-affinity state [17].

In the current study, we developed a direct flow cytometry approach to characterize Ad binding to human platelets, focusing on platelet integrin-mediated binding. Optimization of the methodology could show a number of pertinent findings. First, Ad binding to human platelets can be manipulated *in vitro* by combining a divalent ion and thrombin activation (Fig. 2). Second, Ad binding activates platelets *in vitro* (Fig. 2). Third, an optimal MOI in the order of 10 (Fig. 3) was observed for Ad attachment to the platelet surface (Fig. 4). This optimal MOI is compatible with the ratio of 40 between the spherical surface areas of platelets and Ad, given respective diameters of  $\sim$ 3  $\mu$ m and  $\sim$ 150 nm. Fourth, Ad attachment to human platelets is at


## A. MOI=10




## B. MOI=100



## C. anti-hexon Ab 1:1



## D. anti-hexon Ab 1:8


**Figure 3**

**Optimization of conditions for platelet Ad binding.** Platelets were isolated as above and incubated with Ad (MOI = 10 (a) or MOI = 100 (b), 1 hr, RT, 1:1 antibody dilution). Direct flow cytometry was used to measure Ad binding as FITC-positive platelet events. (c,d) Optimization of the FITC-labeled anti-Ad hexon antibody dilution (c), 1:1 (d) 1:8 dilution, RT, 1-hr]. 1:2 and 1:4 antibody dilutions resulted in levels of Ad binding detection between 1:1 and 1:8 (not shown). Figures representative of  $n = 4$ .


least partially mediated by platelet integrins, as evident by blocking assays using anti- $\alpha$ V $\beta$ 3 monoclonal antibody and RGD peptidomimetics (Fig. 5).

Fifth, although CAR was previously reported to be expressed in human platelets both at the level of RNA and using flow cytometry [2], our studies show CAR deficiency in normal human platelets (Fig. 6).

Because CAR mediates homotypic cell adhesion, it is generally present in specialized intracellular junctions, including the cardiac intercalated disk and the adherens junction of polarized epithelial cells [12]. Although CAR is abundantly expressed in epithelial cells during embryogenesis, its expression in adult mice is restricted to fewer cell types, contrasting with the homogeneous expression pattern of  $\alpha$ V-integrins [18]. Thus, in bone marrow hematopoietic lineages CAR expression is minute [19,20].

**Figure 4**

**Ad binds to the platelet cell surface.** (a) Platelets were incubated with Ad (MOI = 10, 2-hrs) at 4°C or 37°C to compare cell surface binding (4°C) vs. potential cell entry (37°C). Alternatively, platelets were fixed in 4% paraformaldehyde and then measured for cell surface Ad binding using direct flow cytometry. (b) To qualitatively evaluate cell surface Ad binding, Mo cells and platelets were incubated with Ad (MOI = 10, 4°C for Mo cells and RT for platelets, 1-hr) or mock-infected, rinsed, mounted on a cover slip, fixed, blocked with BSA, rinsed, incubated with the FITC-anti-hexon antibody and visualized with a confocal fluorescent microscope. Ad virions adherent to the cell surface were detected as green labeling in Mo cells and orange labeling in platelets. Negative controls included omission of Ad incubation.




**Figure 5**


**Ad binds to human platelets integrin-dependently.** (a) Platelets were isolated, incubated with Ad (black) or AdRGD (red) (MOI = 10, RT) and stained with FITC-labeled anti-hexon antibody as above in Fig. 2. (b) Prior to incubation with AdRGD, platelet integrins were blocked (RT, 1-hr, 150 µg/ml) with the peptides GRGDS (RGD), eptifibatide (a synthetic RGD analog) or C $\gamma$  (a 12-amino acids peptide derived from the carboxy terminus of the FBG  $\gamma$  chain). GRGES served as a negative control. (c) Platelets were first incubated with monoclonal anti- $\alpha$ V $\beta$ 3 or anti-CD41 (=  $\alpha$ IIb $\beta$ 3) antibodies (at 5 or 25 µg/ml), prior to rinse and incubation with AdRGD, rinse and staining with anti-hexon antibody. \*,  $p < 0.05$  for inhibition of Ad attachment with anti- $\alpha$ V $\beta$ 3 antibody. Representative images of at least 2 different experiments ( $n = 3$  for each).




## A. Mo cells, CAR expression




## B. HEK 293 cells, CAR expression



## C. Platelets, CAR expression




## D. Platelets, CD41 expression

**Figure 6**

**CAR expression in platelets.** CAR expression was measured using indirect flow cytometry with a polyclonal rabbit anti-CAR antibody and a secondary FITC labeled antibody. HEK293 cells and Mo melanoma cells served as positive and negative controls for CAR expression, respectively.  $\alpha$ IIb $\beta$ 3 (CD41) expression in normal platelets served as a positive control for platelet receptor expression.

Othman et al employed the RmcB anti-CAR antibody and did not report a CAR-negative cell line to demonstrate the specificity of the anti-CAR antibody [2]. In contrast, we confirmed specificity of the rabbit H-300 polyclonal anti-CAR antibody in both CAR-positive and negative cell lines prior to testing CAR expression in platelets. While variations in the specificity of the anti-CAR antibodies employed may account for the discrepancy between our results and Othman et al [2], further studies are required

to conclusively define CAR expression in human platelets. However, our blocking assays, along with the recent observation that Ad serotype 11 can efficiently bind to mouse platelets fiber-independently [21], further highlight the role of platelet integrins as mediators of Ad binding. Other integrins expressed by platelets include  $\alpha$ 5 $\beta$ 1 and  $\alpha$ 1 $\beta$ 1 [22,23]. While these are not well established as Ad receptors, the recent finding of Ad interference with



**Figure 7**

**Glanzmann thrombasthenia platelets efficiently bind Ad.** (a) Platelets from a patient with Glanzmann thrombasthenia (GT PLT) and normal platelets (Normal PLT) were analyzed for  $\alpha$ IIb $\beta$ 3 expression using indirect flow cytometry. (b) Functional  $\alpha$ IIb $\beta$ 3 deficiency of GT platelets was confirmed by a fibrinogen (FBG) attachment assay. (c) Ad attachment was measured in normal human platelets vs. GT platelets by direct flow cytometry as above in Fig. 2 except for an MOI of 5. \*,  $p < 0.05$  for impaired platelet attachment to FBG. Representative images of at least 2 different experiments ( $n = 3$  for each).

platelet adhesion to fibronectin [2] may suggest that Ad may also bind to the fibronectin receptor  $\alpha 5\beta 1$ .

Previously,  $\alpha \text{IIb}\beta 3$  (gpIIb/IIIa), the primary platelet FBG receptor was reported to mediate platelet attachment of the intracellular bacterial microorganisms, chlamydia and borrelia. These studies employed blocking assays using abciximab (an anti-  $\alpha \text{IIb}\beta 3$  antibody) and RGD peptides [24-26], at 4-400 fold higher blocking concentrations than employed in this study. However, while  $\alpha \text{V}\beta 3$  may partially mediate attachment of Ad to platelets (Fig. 5),  $\alpha \text{IIb}\beta 3$  does not appear to play a significant role in Ad binding to platelets, as evident by lack of blockade by a monoclonal antibody against  $\alpha \text{IIb}\beta 3$  (Fig. 5), and by avid adherence of Ad to  $\alpha \text{IIb}\beta 3$ -deficient platelets from a patient with Glanzmann thrombasthenia (Fig. 7). Of note, unlike borrelia binding to platelets that requires prior platelet activation [24,25], Ad could also efficiently bind to naïve platelets, although platelet activation along with MnCl enhanced Ad binding (Fig. 2).

Glanzmann thrombasthenia (GT) is a rare, inherited disorder of platelet function characterized by mucocutaneous hemorrhage caused by mutations in the  $\alpha \text{IIb}\beta 3$  gene. The major laboratory finding in GT is a profound defect in platelet aggregation caused by a failure of  $\alpha \text{IIb}\beta 3$  to bind FBG. In this study we observed minute expression of  $\alpha \text{IIb}\beta 3$  on platelets from a patient with GT. A typical mutation in this patient's kindred was previously found to completely abolish  $\alpha \text{IIb}\beta 3$  expression while a very low  $\beta 3$  ( $\text{III}\alpha$ ) expression level was still detected [15]. Thus, unlike other  $\alpha \text{IIb}\beta 3$  mutations in other GT kindreds where both  $\alpha \text{IIb}$  and  $\beta 3$  were completely absent, platelets from this GT subpopulation maintain the potential to express some  $\alpha \text{V}\beta 3$  [15]. In this context, while we failed to document substantial  $\alpha \text{V}\beta 3$  expression on normal platelets, Collier et al had measured  $\sim 100$   $\alpha \text{V}\beta 3$  receptors per platelet, i.e. 0.25% of the number of  $\alpha \text{IIb}\beta 3$  receptors per platelet [15].

Our findings on platelet-Ad interaction *in vitro* may have implications on the biodistribution of Ad *in vivo*. Previously, partial platelet depletion did not alter Ad biodistribution and it was postulated that Ad attachment to platelets may occur only in a small fraction of platelets [24]. However, we speculate that blockade of platelet integrins *in vivo* will alter Ad biodistribution. Recently, attachment of Ad particles to platelets resulted in platelet-leukocyte aggregates [3], VWF and p-selectin-mediated thrombocytopenia [2] via clearance by the reticuloendothelial system and the complement pathway [27]. While this scenario may complicate Ad-based gene delivery, it may reflect an evolutionary-conserved defense mechanism allowing to efficiently clear circulating RGD-displaying microorganisms such as Ad. In support of this hypothesis, RGD display on the Ad fiber knob, in addition

to the natural RGD ligand on the Ad penton base, has been reported to result in paradoxically diminished systemic tissue distribution [16]. Thus, fundamental to future rationalized systemic Ad-based gene delivery endeavors in humans is the molecular characterization of Ad-platelet interaction *in vivo*. Additionally, Ad biodistribution and toxicity may differ in GT patients from healthy subjects.

Taken together, we report a direct flow cytometry assay to characterize Ad binding to platelets. This approach may eventually be employed to determine the exact integrin profile accounting for Ad attachment to human platelets and therefore may have implications on systemic Ad biodistribution.

## Methods

### Adenoviral vectors

Ad vectors used in the attachment studies were E1/E3 deleted, replication-deficient serotype 5 Ad vectors. Ad-RGD vector is a capsid-modified Ad, displaying a CDCRGDCDC ligand in the Ad capsid fiber (both from David T. Curiel, University of Alabama at Birmingham). Vector titer was determined by both plaque forming units (PFU) and by spectrophotometric measurement of DNA optical density at 260 nm. The PFU/viral particle ratio was  $\sim 100$  for the Ad vectors.

### Attachment assays

All attachment studies were performed in suspension after initial blocking with BSA. Antibody and peptide blocking assays were performed at 4°C (room temperature [RT] for platelets) with pre-incubation for 1-hr at 5 and 25  $\mu\text{g}/\text{ml}$  or 150  $\mu\text{g}/\text{ml}$ , respectively, as previously described to block cellular  $\alpha \text{V}$  integrins [10,11]. Next, cells were rinsed, incubated with Ad for 1-hr, rinsed and processed for flow cytometry after incubation on ice with FITC-labeled anti-Ad hexon antibody for 1-hr. Attachment of Ad particles to the various Mo cell lines was measured after detaching cells by minimal trypsinization, rinse, resuspension ( $1 \times 10^6$ ) in serum-free medium, incubation with Ad (MOI = 10) at 4°C for 1-hr, rinse and incubation with FITC anti-hexon antibody for 1-hr on ice followed by processing for flow cytometry. Specificity of Ad attachment was confirmed via omission of Ad.

### Antibodies and integrin inhibitors

Anti CD41 (clone 5B12) is a goat monoclonal anti-gpIIb/IIIa antibody (Dako, Carpinteria, CA). LM609 is a function-blocking anti-  $\alpha \text{V}\beta 3$  antibody (Chemicon, Temecula, CA). FITC-labeled anti-Ad hexon antibody was from Chemicon. A rabbit polyclonal anti-CAR antibody (H-300) was from Santa Cruz biotechnology (Santa Cruz, CA). FITC-labeled secondary antibodies were from Jackson Immunoresearch laboratories. FBG was purchased

from Sigma. Eptifibatide (Integrilin®, COR therapeutics Inc, South San Francisco, CA) is a small FBG mimetic primarily antagonizing  $\alpha$ IIB $\beta$ 3 (gpIIB/IIIa), but also  $\alpha$ V integrins [28]. Other FBG peptidomimetic blockers were GRGDS and the FBG-specific 12 amino acid carboxy terminus of the human FBG gamma chain (C $\gamma$ ), HHLG-GAKQAGDV, and the control GRGES peptide, all synthesized by Biosight (Carmiel, Israel).

### Cells

The isogenic cell lines Mo, Mo- $\alpha$ V $\beta$ 3 and Mo- $\alpha$ IIB $\beta$ 3 were a kind gift from Mark H. Ginsberg (The Scripps Research Institute, La Jolla, CA) [13]. These cell lines include the  $\alpha$ V-deficient parental Mo melanoma cell line originally derived from the human melanoma M21 cell line. Mo cells express  $\beta$ 3 integrin mRNA and protein but neither  $\alpha$ V or  $\alpha$ IIB $\beta$ . Mo- $\alpha$ V $\beta$ 3 and Mo- $\alpha$ IIB $\beta$ 3 were generated by Dr. Ginsberg and colleagues from Mo cells by stable expression of  $\alpha$ V or  $\alpha$ IIB $\beta$ , respectively [13]. Thus, while Mo cells express neither  $\alpha$ V $\beta$ 3 nor  $\alpha$ IIB $\beta$ 3, Mo- $\alpha$ V $\beta$ 3 and Mo- $\alpha$ IIB $\beta$ 3 (=Mo  $\alpha$ IIB $\beta$ ) express  $\alpha$ V $\beta$ 3 and  $\alpha$ IIB $\beta$ 3, respectively [29]. We confirmed the specific integrin expression for each cell line (not shown). Of note, the platelet integrin  $\alpha$ IIB $\beta$ 3 is also known as gpIIB/IIIa or CD41.

### Platelet processing

Human blood was collected from healthy, medication-free donors in tri-sodium citrate 3.8%, 1:7 ratio. Platelet rich plasma (PRP) was prepared as before [30] with the following modifications. Briefly, blood was centrifuged at 800 rpm for 15 minutes, PRP collected and further centrifuged at 5000 rpm for 4 minutes in the presence of citrate (5 mM). The platelet pellet was resuspended in magnesium-free and calcium-free PBS with citrate (final concentration 5 mM). Platelets were counted and studied microscopically to exclude aggregates and contaminating cells. When indicated, thrombin (Sigma, 0.5 U/ml, 20 min, RT) was used to activate platelets. Platelet activation was measured by annexin v flow cytometry [14]. To evaluate Ad attachment to gpIIB/IIIa-deficient platelets, following informed consent, blood was obtained from a previously-diagnosed, 31-yr-old male with Glanzmann thrombasthenia (GT), simultaneously with blood drawn from a healthy control and processed as above. GT platelets manifested deficient gpIIB/IIIa expression, platelet attachment to FBG and activation. FBG-platelet attachment assay was performed in 96-well plates after pre-coating with 50 ml of 50 microgram/ml FBG solution overnight at 4°C and blocking with BSA 1%. Normal or GT platelets ( $2 \times 10^6$ ) were then incubated for 1-hr at 37°C, rinsed, fixed and counted.

### Flow cytometry

Indirect flow cytometry was performed to measure membrane-bound Ad particles. Platelets were pre-defined and

gated by both their characteristic forward light scatter and labeling with an anti-CD41 ( $\alpha$ IIB $\beta$ 3) antibody. Binding of Ad particles to platelets was identified by FITC fluorescence above a threshold value set as the maximal background fluorescence, predetermined by analysis of platelet FITC fluorescence, as previously described for other microorganisms [24-26].

Ad binding to nucleated cells was evaluated similarly with the exception that cells were diluted to  $1 \times 10^6$ /ml and Ad incubation was performed at 4°C for 1-hr [10]. Event data were collected from each sample with scatter data in linear mode and fluorescent data in logarithmic mode. Data were analyzed using forward and side scatter gates to exclude dead cells and cell fragments. Fluorescence histograms or dot plots were generated from the gated population and percentage of positive events was used to determine differences between cell samples.

### Immunofluorescence

Cells and normal platelets were incubated with Ad (MOI = 10, 4°C, 1-hr) or mock-incubated, mounted on a cover slip and visualized with a confocal fluorescent microscope. FITC-positive labeling was observed only in cells incubated with Ad.

### Statistical analysis

Experiments were repeated two to three times. Representative flow cytometry images are presented. Where indicated,  $p < 0.05$  was considered statistically significant.

### Abbreviations

gpIIB/IIIa:  $\alpha$ IIB $\beta$ 3; Ad: Adenovirus; FBG: fibrinogen; C $\gamma$ : carboxy terminus of the human FBG gamma chain; CAR: Coxsackie adenoviral receptor; GT: Glanzmann thrombasthenia; MOI: multiplicity of infection; RT: room temperature.

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

NS designed study, performed experiments and wrote manuscript, GE performed experiments, DKG intellectual contribution and reagents, LK performed experiments, SUS intellectual contribution and provided cell lines, YSH designed experiments and wrote manuscript.

### Acknowledgements

We thank Prof. David Varon and Ms. Ella Shai (Dept. of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel) for helpful discussions and platelet isolation protocols. Funding was provided by the German-Israeli Foundation grant no. 817/2004, Israel Science Foundation grant no. 573/03, the Israeli Ministry of Health, Chief Scientist Office, and the Hadassah Women's health fund (to YSH).

## References

1. Eggerman TL, Mondoro TH, Lozier JN, Vostal JG: **Adenoviral vectors do not induce, inhibit, or potentiate human platelet aggregation.** *Human Gene Therapy* 2002, **13**:125-128.
2. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D: **Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.** *Blood* 2007, **109**:2832-2839.
3. Stone D, Liu Y, Shayakhmetov D, Li ZY, Ni S, Lieber A: **Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver.** *Journal of Virology* 2007, **81**:4866-4871.
4. Wolins N, Lozier J, Eggerman TL, Jones E, Aguilar-Cordova E, Vostal JG: **Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance.** *British Journal of Haematology* 2003, **123**:903-905.
5. Fox G, Parry NR, Barnett PV, McGinn B, Rowlands DJ, Brown F: **The Cell Attachment Site on Foot-And-Mouth-Disease Virus Includes the Amino-Acid Sequence Rgd (Arginine-Glycine-Aspartic Acid).** *Journal of General Virology* 1989, **70**:625-637.
6. Bergelson JM, Shepley MP, Chan BMC, Hemler ME, Finberg RW: **Identification of the Integrin  $\alpha$ V $\beta$ 2 As A Receptor for Echovirus-1.** *Science* 1992, **255**:1718-1720.
7. Isberg RR: **Discrimination Between Intracellular Uptake and Surface-Adhesion of Bacterial Pathogens.** *Science* 1991, **252**:934-938.
8. Relman D, Tuomanen E, Falkow S, Golenbock DT, Saukkonen K, Wright SD: **Recognition of A Bacterial Adhesin by An Integrin – Macrophage Cr3 (Alpha-M-Beta-2, Cd11B Cd18) Binds Filamentous Hemagglutinin of Bordetella-Pertussis.** *Cell* 1990, **61**:1375-1382.
9. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: **Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5.** *Science* 1997, **275**:1320-1323.
10. Wickham TJ, Mathias P, Cheresch DA, Nemerow GR: **Integrin-Alpha-V-Beta-3 and Integrin-Alpha-V-Beta-5 Promote Adenovirus Internalization But Not Virus Attachment.** *Cell* 1993, **73**:309-319.
11. Wickham TJ, Filardo EJ, Cheresch DA, Nemerow GR: **Integrin Alpha-V-Beta-5 Selectively Promotes Adenovirus-Mediated Cell-Membrane Permeabilization.** *Journal of Cell Biology* 1994, **127**:257-264.
12. Zhang YM, Bergelson JM: **Adenovirus receptors.** *Journal of Virology* 2005, **79**:12125-12131.
13. Chen YP, O'toole TE, Leong L, Liu BQ, Diaz-Gonzalez F, Ginsberg MH: **Beta(3) Integrin-Mediated Fibrin Clot Retraction by Nucleated Cells – Differing Behavior of Alpha(IIb)Beta(3) and Alpha(V)Beta(3).** *Blood* 1995, **86**:2606-2615.
14. Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz EA, Guillin MC, Eldor A: **In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with  $\beta$ -thassaemia major.** *Br J Haematol* 1997, **98**(1):51-56.
15. Coller BS, Cheresch DA, Asch E, Seligsohn U: **Platelet Vitronectin Receptor Expression Differentiates Iraqi-Jewish from Arab Patients with Glanzmann Thrombasthenia in Israel.** *Blood* 1991, **77**:75-83.
16. Murakami S, Sakurai F, Kawabata K, Okada N, Fujita T, Yamamoto A, Hayakawa T, Mizuguchi H: **Interaction of penton base Arg-Gly-Asp motifs with integrins is crucial for adenovirus serotype 35 vector transduction in human hematopoietic cells.** *Gene Therapy* 2007, **14**:1525-1533.
17. Hantgan RR, Stahle MC, Connor JH, Horita DA, Rocco M, McLane MA, Yakovlev S, Medved L: **Integrin alpha IIb beta 3: ligand interactions are linked to binding-site remodeling.** *Protein Science* 2006, **15**:1893-1906.
18. Fechner H, Haack A, Wang A, Wang X, Eizema K, Pauschinger M, Schoemaker R, Veghel R, Houtsmuller A, Schultheiss HP, Lamers J, Poller W: **Expression of Coxsackie adenovirus receptor and  $\alpha$ v $\beta$ 3-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers.** *Gene Therapy* 1999, **6**(9):1520-1535.
19. Seiradake E, Henaff D, Wodrich H, Billet O, Perreau M, Hippert C, Mennechet F, Schoehn G, Lortat-Jacob H, Dreja H, Ibanes S, Kalatzis V, Wang JP, Finberg RW, Cusack S, Kremer EJ: **The Cell Adhesion Molecule "CAR" and Sialic Acid on Human Erythrocytes Influence Adenovirus In Vivo Biodistribution.** *PLoS Pathogens* 2009, **5**(1):e1000277.
20. Tallone T, Malin S, Samuelsson A, Wilbertz J, Miyahara M, Okamoto K, Poellinger L, Philipson L, Pettersson S: **A mouse model for adenovirus gene delivery.** *PNAS* 2001, **98**(14):7910-7915.
21. Stone D, Liu Y, Li Zy, Tuve S, Strauss R, Lieber A: **Comparison of adenovirus from species B, C, E, and F after intravenous delivery.** *Molecular Therapy* 2007, **15**:2146-2153.
22. Lawler J, Hynes RO: **An Integrin Receptor on Normal and Thrombasthenic Platelets That Binds Thrombospondin.** *Blood* 1989, **74**:2022-2027.
23. Santoro SA, Rajpara SM, Staatz WD, Woods VL: **Isolation and Characterization of A Platelet Surface Collagen Binding Complex Related to  $\alpha$ V $\beta$ 2.** *Biochemical and Biophysical Research Communications* 1988, **153**:217-223.
24. Coburn J, Leong JM, Erban JK: **Integrin Alpha-IIb-Beta-3 Mediates Binding of the Lyme-Disease Agent Borrelia-Burgdorferi to Human Platelets.** *PNAS* 1993, **90**:7059-7063.
25. Alugupalli KR, Michelson AD, Barnard MR, Robbins D, Coburn J, Baker EK, Ginsberg MH, Schwan TG, Leong JM: **Platelet activation by a relapsing fever spirochaete results in enhanced bacterium-platelet interaction via integrin alpha(IIb)beta(3) activation.** *Molecular Microbiology* 2001, **39**:330-340.
26. Kalvegren H, Majeed M, Bengtsson T: **Chlamydia pneumoniae binds to platelets and triggers P-selectin expression and aggregation – A causal role in cardiovascular disease? Arteriosclerosis Thrombosis and Vascular Biology 2003, **23**:1677-1683.**
27. Kiang A, Hartman ZC, Everett RS, Serra D, Jiang H, Frank MM, Amalfitano A: **Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system.** *Molecular Therapy* 2006, **14**:588-598.
28. Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Annizzi L, Arfsten A, Campbell AM, Charo IF: **Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein.** *J Biol Chem* 1993, **268**(2):1066-73.
29. Urieli-Shoval S, Shubinsky G, Linke RP, Fridkin M, Tabi I, Matzner Y: **Adhesion of human platelets to serum amyloid A.** *Blood* 2002, **99**:1224-1229.
30. Peerschke EI, Silver T, Weksler BB, Yin W, Bernhardt B, Varon D: **Examination of platelet function in whole blood under dynamic flow conditions with the cone and plate(let) analyzer – Effect of erythrocytosis and thrombocytosis.** *American Journal of Clinical Pathology* 2007, **127**:422-428.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
http://www.biomedcentral.com/info/publishing\_adv.asp

